Increased risk of pancreatic cancer in patients with metabolic syndrome could be due to lower levels of adiponectin (a protein hormone linked to glucose level regulation and fatty acid breakdown), which results in a lack of insulin-sensitizing and anti-inflammatory capabilities33. Here, INS is linked to pancreatic neoplasm.